BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Visca D, Ong CWM, Tiberi S, Centis R, D'Ambrosio L, Chen B, Mueller J, Mueller P, Duarte R, Dalcolmo M, Sotgiu G, Migliori GB, Goletti D. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology 2021;27:151-65. [PMID: 33547029 DOI: 10.1016/j.pulmoe.2020.12.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Sharma S, Takkella D, Kumar P, Gavvala K. Spectroscopic Analysis to Identify the Binding Site for Rifampicin on Bovine Serum Albumin. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2022. [DOI: 10.1016/j.saa.2022.121721] [Reference Citation Analysis]
2 Tanoue Y, Ghaznavi C, Kawashima T, Eguchi A, Yoneoka D, Nomura S. Changes in Health Care Access during the COVID-19 Pandemic: Estimates of National Japanese Data, June 2020–October 2021. IJERPH 2022;19:8810. [DOI: 10.3390/ijerph19148810] [Reference Citation Analysis]
3 Kaforou M, Broderick C, Vito O, Levin M, Scriba TJ, Seddon JA. Transcriptomics for child and adolescent tuberculosis. Immunol Rev 2022. [PMID: 35818983 DOI: 10.1111/imr.13116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sotgiu G, Mondoni M. TB/Covid-19: An Underestimated Risk? Archivos de Bronconeumología 2022. [DOI: 10.1016/j.arbres.2022.07.006] [Reference Citation Analysis]
5 Souza MDR, Paz WSD, Sales VBDS, Jesus GFHD, Tavares DDS, Lima SVMA, Sousa ÁFL, Melo EVD, Carmo RFD, Souza CDFD, Bezerra-santos M. Impact of the COVID-19 Pandemic on the Diagnosis of Tuberculosis in Brazil: Is the WHO End TB Strategy at Risk? Front Pharmacol 2022;13:891711. [DOI: 10.3389/fphar.2022.891711] [Reference Citation Analysis]
6 Wang Q, Guo S, Wei X, Dong Q, Xu N, Li H, Zhao J, Sun Q. Global prevalence, treatment and outcome of tuberculosis and COVID-19 coinfection: a systematic review and meta-analysis (from November 2019 to March 2021). BMJ Open 2022;12:e059396. [PMID: 35725250 DOI: 10.1136/bmjopen-2021-059396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shah T, Shah Z, Yasmeen N, Baloch Z, Xia X. Pathogenesis of SARS-CoV-2 and Mycobacterium tuberculosis Coinfection. Front Immunol 2022;13:909011. [DOI: 10.3389/fimmu.2022.909011] [Reference Citation Analysis]
8 Mekonen KG, Obsu LL, Habtemichael TG. Optimal control analysis for the coinfection of COVID-19 and TB. Arab Journal of Basic and Applied Sciences 2022;29:175-92. [DOI: 10.1080/25765299.2022.2085445] [Reference Citation Analysis]
9 Jamwal A, Mohanty A, Swami A, Turbadkar D. Impact of COVID-19 on tuberculosis services: an experience from a tertiary care hospital. J Med Microbiol 2022;71. [PMID: 35737515 DOI: 10.1099/jmm.0.001559] [Reference Citation Analysis]
10 Utomo B, Chan CK, Mertaniasih NM, Soedarsono S, Fauziyah S, Sucipto TH, Aquaresta F, Eljatin DS, Adnyana IMDM. Comparison Epidemiology between Tuberculosis and COVID-19 in East Java Province, Indonesia: An Analysis of Regional Surveillance Data in 2020. TropicalMed 2022;7:83. [DOI: 10.3390/tropicalmed7060083] [Reference Citation Analysis]
11 Leidman E, Doocy S, Heymsfield G, Sebushishe A, Mbong EN, Majer J, Bollemeijer I; IMC-CDC COVID-19 Research Team. Risk factors for hospitalisation and death from COVID-19: a prospective cohort study in South Sudan and Eastern Democratic Republic of the Congo. BMJ Open 2022;12:e060639. [PMID: 35584876 DOI: 10.1136/bmjopen-2021-060639] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Scholze AR, Dália Alves J, Berra TZ, Santos FLD, Ramos ACV, Lima de Freitas G, José Quina Galdino M, Meneguetti Pieri F, Augusto Moraes Arcoverde M, Cristina Pillon S, Monroe AA, Fronteira I, Gomes D, Alexandre Arcêncio R. The burden of alcohol, tobacco and others drugs among incarcerated population diagnosed with tuberculosis: time trends and spatial determinants in Southern Brazil. BMC Public Health 2022;22:999. [PMID: 35581564 DOI: 10.1186/s12889-022-13408-1] [Reference Citation Analysis]
13 Prasad P, Mahapatra S, Mishra R, Murmu KC, Aggarwal S, Sethi M, Mohapatra P, Ghosh A, Yadav R, Dodia H, Ansari SA, De S, Singh D, Suryawanshi A, Dash R, Senapati S, Beuria TK, Chattopadhyay S, Syed GH, Swain R, Raghav SK, Parida A. Long-read 16S-seq reveals nasopharynx microbial dysbiosis and enrichment of Mycobacterium and Mycoplasma in COVID-19 patients: a potential source of co-infection. Mol Omics 2022. [PMID: 35506682 DOI: 10.1039/d2mo00044j] [Reference Citation Analysis]
14 Martins M, Carvalho L, Carvalho T, Gomes I. Impact of the COVID-19 pandemic on in-hospital diagnosis of tuberculosis in non-HIV patients. Pulmonology 2022. [DOI: 10.1016/j.pulmoe.2022.04.012] [Reference Citation Analysis]
15 Parolina L, Pshenichnaya N, Vasilyeva I, Lizinfed I, Urushadze N, Guseva V, Otpushchennikova O, Dyachenko O, Kharitonov P. Clinical characteristics of COVID-19 in patients with tuberculosis and factors associated with the disease severity. Int J Infect Dis 2022:S1201-9712(22)00232-6. [PMID: 35483555 DOI: 10.1016/j.ijid.2022.04.041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Angelova VT, Pencheva T, Vassilev N, K-Yovkova E, Mihaylova R, Petrov B, Valcheva V. Development of New Antimycobacterial Sulfonyl Hydrazones and 4-Methyl-1,2,3-thiadiazole-Based Hydrazone Derivatives. Antibiotics (Basel) 2022;11:562. [PMID: 35625207 DOI: 10.3390/antibiotics11050562] [Reference Citation Analysis]
17 Sereda Y, Korotych O, Klimuk D, Zhurkin D, Solodovnikova V, Grzemska M, Grankov V, Hurevich H, Yedilbayev A, Skrahina A. Tuberculosis Co-Infection Is Common in Patients Requiring Hospitalization for COVID-19 in Belarus: Mixed-Methods Study. Int J Environ Res Public Health 2022;19:4370. [PMID: 35410048 DOI: 10.3390/ijerph19074370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Hashem MK, Hussein AARM, Amin MT, Mahmoud A, Shaddad AM. The burden of COVID-19 pandemic on tuberculosis detection: a single-center study. Egypt J Bronchol 2022;16. [DOI: 10.1186/s43168-022-00117-x] [Reference Citation Analysis]
19 Sivakumaran D, Jenum S, Ritz C, Vaz M, Doherty TM, Grewal HMS. Improving Assignments for Therapeutic and Prophylactic Treatment Within TB Households. A Potential for Immuno-Diagnosis? Front Immunol 2022;13:801616. [DOI: 10.3389/fimmu.2022.801616] [Reference Citation Analysis]
20 Dass SA, Balakrishnan V, Arifin N, Lim CSY, Nordin F, Tye GJ. The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic. Front Immunol 2022;13:833715. [PMID: 35242137 DOI: 10.3389/fimmu.2022.833715] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Nasiri MJ, Zangiabadian M, Arabpour E, Amini S, Khalili F, Centis R, D'Ambrosio L, Denholm JT, Schaaf HS, van den Boom M, Kurhasani X, Dalcolmo MP, Al-Abri S, Chakaya J, Alffenaar JW, Akkerman O, Silva DR, Muňoz-Torrico M, Seaworth B, Pontali E, Saderi L, Tiberi S, Zumla A, Migliori GB, Sotgiu G. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. Int J Infect Dis 2022:S1201-9712(22)00125-4. [PMID: 35245659 DOI: 10.1016/j.ijid.2022.02.043] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Luke E, Swafford K, Shirazi G, Venketaraman V. TB and COVID-19: An Exploration of the Characteristics and Resulting Complications of Co-infection. Front Biosci (Schol Ed) 2022;14:6. [PMID: 35320917 DOI: 10.31083/j.fbs1401006] [Reference Citation Analysis]
23 Patra K, Batabyal S, Mandal K, Ghose D, Sarkar J. Tuberculosis and COVID-19: A combined global threat to human civilization. Clinical Epidemiology and Global Health 2022. [DOI: 10.1016/j.cegh.2022.101031] [Reference Citation Analysis]
24 Torres PPTES, Rabahi MF. Tuberculose em tempos de COVID-19: não podemos perder o foco no diagnóstico. Radiol Bras 2022;55:1-2. [DOI: 10.1590/0100-3984.2022.55.2e1] [Reference Citation Analysis]
25 Mtetwa HN, Amoah ID, Kumari S, Bux F, Reddy P. Molecular surveillance of tuberculosis-causing mycobacteria in wastewater. Heliyon 2022;8:e08910. [PMID: 35198775 DOI: 10.1016/j.heliyon.2022.e08910] [Reference Citation Analysis]
26 Gil-Manso S, Miguens Blanco I, López-Esteban R, Carbonell D, López-Fernández LA, West L, Correa-Rocha R, Pion M. Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals. Front Immunol 2021;12:793142. [PMID: 35069575 DOI: 10.3389/fimmu.2021.793142] [Reference Citation Analysis]
27 Bostanghadiri N, Jazi FM, Razavi S, Fattorini L, Darban-sarokhalil D. Mycobacterium tuberculosis and SARS-CoV-2 Coinfections: A Review. Front Microbiol 2022;12:747827. [DOI: 10.3389/fmicb.2021.747827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Guirelli AO, Bispo TR, Colpas DR, de Campos IB, Chimara E, Cergole-Novella MC, Rodart IF, Dos Santos Candido V, Segura-Ramírez PJ, Dos Santos Menezes Gaiotto Daros V, Dos Santos Carmo AM. Tuberculosis/COVID-19 co-infection detected in a single sputum sample using a rapid molecular test. Braz J Microbiol 2022. [PMID: 35107805 DOI: 10.1007/s42770-021-00677-y] [Reference Citation Analysis]
29 Galvin J, Tiberi S, Akkerman O, Kerstjens H, Kunst H, Kurhasani X, Ambrosino N, Migliori G. Pulmonary tuberculosis in intensive care setting, with a focus on the use of severity scores, a multinational collaborative systematic review. Pulmonology 2022. [DOI: 10.1016/j.pulmoe.2022.01.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
30 Migliori GB, Tiberi S, Duarte R. Investigating the response to COVID-19 and understanding severe TB cases: the 2022 Pulmonology TB series. Pulmonology 2022. [DOI: 10.1016/j.pulmoe.2022.01.018] [Reference Citation Analysis]
31 Mançano AD, Zanetti G, Marchiori E. Concomitant COVID-19 and pulmonary tuberculosis: computed tomography aspects. Radiol Bras 2022;55:1-5. [DOI: 10.1590/0100-3984.2021.0070] [Reference Citation Analysis]
32 Rodrigues I, Aguiar A, Migliori GB, Duarte R. Impact of the COVID-19 pandemic on tuberculosis services. Pulmonology 2022. [DOI: 10.1016/j.pulmoe.2022.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Caren GJ, Iskandar D, Pitaloka DA, Abdulah R, Suwantika AA. COVID-19 Pandemic Disruption on the Management of Tuberculosis Treatment in Indonesia. JMDH 2022;Volume 15:175-83. [DOI: 10.2147/jmdh.s341130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
34 Koupaei M, Naimi A, Moafi N, Mohammadi P, Tabatabaei FS, Ghazizadeh S, Heidary M, Khoshnood S. Clinical Characteristics, Diagnosis, Treatment, and Mortality Rate of TB/COVID-19 Coinfectetd Patients: A Systematic Review. Front Med (Lausanne) 2021;8:740593. [PMID: 34926494 DOI: 10.3389/fmed.2021.740593] [Reference Citation Analysis]
35 Aguillón-Durán GP, Prieto-Martínez E, Ayala D, García J Jr, Thomas JM 3rd, García JI, Henry BM, Torrelles JB, Turner J, Ledezma-Campos E, Restrepo BI. COVID-19 and chronic diabetes: the perfect storm for reactivation tuberculosis?: a case series. J Med Case Rep 2021;15:621. [PMID: 34915933 DOI: 10.1186/s13256-021-03193-7] [Reference Citation Analysis]
36 Nabity SA, Han E, Lowenthal P, Henry H, Okoye N, Chakrabarty M, Chitnis AS, Kadakia A, Villarino E, Low J, Higashi J, Barry PM, Jain S, Flood J. Sociodemographic Characteristics, Comorbidities, and Mortality Among Persons Diagnosed With Tuberculosis and COVID-19 in Close Succession in California, 2020. JAMA Netw Open 2021;4:e2136853. [PMID: 34860244 DOI: 10.1001/jamanetworkopen.2021.36853] [Reference Citation Analysis]
37 Vega C. From Hume to Wuhan: An Epistemological Journey on the Problem of Induction in COVID-19 Machine Learning Models and its Impact Upon Medical Research. IEEE Access 2021;9:97243-50. [PMID: 34812399 DOI: 10.1109/ACCESS.2021.3095222] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: description of the global cohort. Eur Respir J 2021:2102538. [PMID: 34764184 DOI: 10.1183/13993003.02538-2021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Nandan A, Siddiqui NA, Singh C, Aeri A, Gwenzi W, Ighalo JO, de Carvalho Nagliate P, Meili L, Singh P, Chaukura N, Rangabhashiyam S. COVID-19 pandemic in Uttarakhand, India: Environmental recovery or degradation? J Environ Chem Eng 2021;9:106595. [PMID: 34692403 DOI: 10.1016/j.jece.2021.106595] [Reference Citation Analysis]
40 Bongomin F, Sereke SG, Okot J, Katsigazi R, Kandole TK, Oriekot A, Olum R, Atukunda A, Baluku JB, Nakwagala F. COVID-19, HIV-Associated Cryptococcal Meningitis, Disseminated Tuberculosis and Acute Ischaemic Stroke: A Fatal Foursome. Infect Drug Resist 2021;14:4167-71. [PMID: 34675561 DOI: 10.2147/IDR.S335711] [Reference Citation Analysis]
41 Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM, Allwood B, Byrne AL, Mortimer K, Wallis RS, Fox GJ, Leung CC, Chakaya JM, Seaworth B, Rachow A, Marais BJ, Furin J, Akkerman OW, Al Yaquobi F, Amaral AFS, Borisov S, Caminero JA, Carvalho ACC, Chesov D, Codecasa LR, Teixeira RC, Dalcolmo MP, Datta S, Dinh-Xuan AT, Duarte R, Evans CA, García-García JM, Günther G, Hoddinott G, Huddart S, Ivanova O, Laniado-Laborín R, Manga S, Manika K, Mariandyshev A, Mello FCQ, Mpagama SG, Muñoz-Torrico M, Nahid P, Ong CWM, Palmero DJ, Piubello A, Pontali E, Silva DR, Singla R, Spanevello A, Tiberi S, Udwadia ZF, Vitacca M, Centis R, D Ambrosio L, Sotgiu G, Lange C, Visca D. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis 2021;25:797-813. [PMID: 34615577 DOI: 10.5588/ijtld.21.0425] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Abdullahi M, Das N, Adeniji SE, Usman AK, Sani AM. In-silico design and ADMET predictions of some new imidazo[1,2-a]pyridine-3-carboxamides (IPAs) as anti-tubercular agents. J Clin Tuberc Other Mycobact Dis 2021;25:100276. [PMID: 34568589 DOI: 10.1016/j.jctube.2021.100276] [Reference Citation Analysis]
43 Alves A, Aguiar A, Migliori GB, Duarte R. COVID-19 related hospital re-organization and trends in tuberculosis diagnosis and admissions: reflections from Portugal. Arch Bronconeumol (Engl Ed) 2021. [PMID: 34602700 DOI: 10.1016/j.arbres.2021.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Sentís A, Prats-Uribe A, Peixoto VR, Caylà JA, Gomes MD, Sousa S, Duarte R, Carvalho I, Carvalho C. Decline of tuberculosis notification rate in different populations and regions in Portugal, 2010-2017. Pulmonology 2021:S2531-0437(21)00158-6. [PMID: 34544672 DOI: 10.1016/j.pulmoe.2021.08.002] [Reference Citation Analysis]
45 Szlósarczyk M, Piech R, Milc A, Hubicka U. Fast and Sensitive Voltammetric Method for the Determination of Rifampicin on Renewable Amalgam Film Electrode. Sensors (Basel) 2021;21:5792. [PMID: 34502683 DOI: 10.3390/s21175792] [Reference Citation Analysis]
46 Abdoli A, Falahi S, Kenarkoohi A. COVID-19-associated opportunistic infections: a snapshot on the current reports. Clin Exp Med 2021. [PMID: 34424451 DOI: 10.1007/s10238-021-00751-7] [Reference Citation Analysis]
47 Rajamanickam A, Kumar NP, Padmapriyadarsini C, Nancy A, Selvaraj N, Karunanithi K, Munisankar S, Bm S, Renji RM, Ambu TC, Venkataramani V, Babu S. Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection. J Infect 2021;83:339-46. [PMID: 34329676 DOI: 10.1016/j.jinf.2021.07.029] [Reference Citation Analysis]
48 Fonseca CA Jr, Zanetti G, Marchiori E. Pulmonary Tuberculosis in a Patient with COVID-19 Pneumonia. Rev Soc Bras Med Trop 2021;54:e03142021. [PMID: 34231776 DOI: 10.1590/0037-8682-0314-2021] [Reference Citation Analysis]
49 Riou C, du Bruyn E, Stek C, Daroowala R, Goliath RT, Abrahams F, Said-Hartley Q, Allwood BW, Hsiao NY, Wilkinson KA, Arlehamn CSL, Sette A, Wasserman S, Wilkinson RJ; HIATUS consortium. Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. J Clin Invest 2021;131:149125. [PMID: 33945513 DOI: 10.1172/JCI149125] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
50 Chopra KK, Matta S, Arora VK. Impact of second wave of Covid-19 on tuberculosis control. Indian J Tuberc 2021;68:311-2. [PMID: 34099194 DOI: 10.1016/j.ijtb.2021.05.001] [Reference Citation Analysis]
51 Kant S, Tyagi R. The impact of COVID-19 on tuberculosis: challenges and opportunities. Ther Adv Infect Dis 2021;8:20499361211016973. [PMID: 34178322 DOI: 10.1177/20499361211016973] [Reference Citation Analysis]
52 McQuaid CF, Vassall A, Cohen T, Fiekert K, White RG. The impact of COVID-19 on TB: a review of the data. Int J Tuberc Lung Dis 2021;25:436-46. [PMID: 34049605 DOI: 10.5588/ijtld.21.0148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
53 Wee LE, Goh KCM, Conceicao EP, Tan JBX, Sng LH, Venkatachalam I. Increased detection of pulmonary tuberculosis amongst hospitalised inpatients during the COVID-19 pandemic. Eur Respir J 2021;57:2100616. [PMID: 34016605 DOI: 10.1183/13993003.00616-2021] [Reference Citation Analysis]
54 Silva DR, Mello FCQ, D'Ambrosio L, Centis R, Dalcolmo MP, Migliori GB. Tuberculosis and COVID-19, the new cursed duet: what differs between Brazil and Europe? J Bras Pneumol 2021;47:e20210044. [PMID: 33950095 DOI: 10.36416/1806-3756/e20210044] [Reference Citation Analysis]
55 Silva DR, Mello FCQ, Migliori GB. Tuberculosis Series 2021. J Bras Pneumol 2021;47:e20210109. [PMID: 33950097 DOI: 10.36416/1806-3756/e20210109] [Reference Citation Analysis]
56 Santos FLD, Souza LLL, Bruce ATI, Crispim JA, Arroyo LH, Ramos ACV, Berra TZ, Alves YM, Scholze AR, Costa FBPD, Martoreli Júnior JF, Moncaio ACS, Pinto IC, Arcêncio RA. Patients' perceptions regarding multidrug-resistant tuberculosis and barriers to seeking care in a priority city in Brazil during COVID-19 pandemic: A qualitative study. PLoS One 2021;16:e0249822. [PMID: 33836024 DOI: 10.1371/journal.pone.0249822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Tiberi S, Vjecha MJ, Zumla A, Galvin J, Migliori GB, Zumla A. Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. Int J Infect Dis 2021:S1201-9712(21)00153-3. [PMID: 33713815 DOI: 10.1016/j.ijid.2021.02.067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
58 Duarte R, Aguiar A, Pinto M, Furtado I, Tiberi S, Lönnroth K, Migliori GB. Different disease, same challenges: Social determinants of tuberculosis and COVID-19. Pulmonology 2021;27:338-44. [PMID: 33648891 DOI: 10.1016/j.pulmoe.2021.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
59 Migliori GB, Visca D, van den Boom M, Tiberi S, Silva DR, Centis R, D'Ambrosio L, Thomas T, Pontali E, Saderi L, Schaaf HS, Sotgiu G; contributing members of the Global Tuberculosis Network. Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology 2021;27:248-56. [PMID: 33547028 DOI: 10.1016/j.pulmoe.2020.12.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]